IPO Timeline
Broker Results (T-2)
2022-02-21
Some brokers release in afternoon
Grey Market (T-1)
2022-02-22
Afternoon
HKEX Allotment (T-1)
2022-02-22
Evening
Registrar Allotment (T-1)
2022-02-22
Evening
Listing Day (T)
2022-02-23
First day of trading
Company Overview
| Stock Name | 樂普生物科技股份有限公司 - B - H股 |
|---|---|
| Stock Code | 02157 |
| Company Full Name | 樂普生物科技股份有限公司 - B - H股 |
| Industry | 醫療保健 |
| Principal Activities | 主要從事生物制藥業務，專注於腫瘤療法。 |
| Listing Date | 2022-02-23 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市松江區莘磚公路518號41號樓2層 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.lepubiopharma.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 7.13 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 43.1% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 90,465,440 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 7.14 |
|---|---|
| First Day Open | HK$ 7.13 |
| First Day Change | 0.14% |
| First Day Volume | 15827000.0 |
| First Day Turnover | 112031000.0 |
Use of Proceeds
| Use of Proceeds | 1、將分配約551.0百萬港元（占所得款項凈額的68.5%）為核心產品撥資； 2、將分配約51.0百萬港元（占所得款項凈額的6.3%）為公司的其他主要臨床階段候選藥物及公司的主要臨床前候選藥物撥資； 3、將分配約127.0百萬港元（占所得款項凈額的15.8%）用于收購有潛力的技術及資產及擴張公司的候選藥物管線； 4、將分配約75.2百萬港元（占所得款項凈額的9.4%）用作一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
中国国际金融香港证券有限公司 CE AEN894
摩根士丹利亚洲有限公司 CE AAD291
Overall Coordinators (2)
中国国际金融香港证券有限公司 CE AEN894
摩根士丹利亚洲有限公司 CE AAD291
Joint Bookrunners (6)
中国国际金融香港证券有限公司 CE AEN894
摩根士丹利亚洲有限公司 CE AAD291
海通国际证券有限公司 CE AAF806
华泰金融控股（香港）有限公司 CE AOK809
中国银河国际证券（香港）有限公司 CE AXM459
华盛资本证券有限公司 CE AUL711
Joint Lead Managers (7)
中国国际金融香港证券有限公司 CE AEN894
摩根士丹利亚洲有限公司 CE AAD291
海通国际证券有限公司 CE AAF806
华泰金融控股（香港）有限公司 CE AOK809
中国银河国际证券（香港）有限公司 CE AXM459
华盛资本证券有限公司 CE AUL711
老虎证券（香港）环球有限公司 CE BMU940
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | King Star Med LP | 155,854,670 HKD | — | 17.23% | — | 6 months | 2022-08-23 |
| 2 | Vivo Funds | 233,785,570 HKD | — | 25.84% | — | 6 months | 2022-08-23 |
Directors & Management
| Chairman | 蒲忠杰 |
|---|---|
| Company Secretary | 李昀軼;黎少娟 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 蒲忠杰(39.69%);胡朝紅(8.37%);蘇榮譽(6.03%);蒲玨(5.42%) |
|---|
IPO Timeline
